Ceftazidime-Avibactam is Strongly Preferred Over Tigecycline Plus Colistin for CRE Infections
For severe carbapenem-resistant Enterobacterales (CRE) infections, ceftazidime-avibactam should be used as monotherapy rather than tigecycline plus colistin combination therapy, based on superior efficacy, lower mortality, and better safety profile.
Evidence-Based Rationale
Guideline Recommendations (Highest Priority)
The 2022 ESCMID guidelines provide clear direction 1:
- For severe CRE infections: Ceftazidime-avibactam or meropenem-vaborbactam are conditionally recommended if active in vitro (moderate/low quality evidence)
- Against tigecycline: Specifically recommend NOT using tigecycline for bloodstream infections (BSI) and hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) - conditional recommendation with low-quality evidence
- Against combination therapy: Strong recommendation AGAINST combination therapy when using ceftazidime-avibactam for susceptible CRE (low-quality evidence)
- Polymyxin-based combinations: Only suggested when CRE is susceptible in vitro ONLY to polymyxins, aminoglycosides, tigecycline, or fosfomycin, OR when newer agents are unavailable (conditional, moderate quality)
Critical Safety Concerns with Tigecycline
The FDA drug label reveals concerning mortality signals 2:
- All-cause mortality: 4.0% with tigecycline vs. 3.0% with comparators
- Adjusted risk difference: 0.6% (95% CI 0.1-1.2) excess mortality
- Particularly problematic in HAP: 14.1% mortality vs. 12.2% with comparators
- VAP subgroup: 19.1% mortality vs. 12.3% with comparators
- Higher rates of sepsis/septic shock: 2% vs. 1% with comparators
Clinical Outcomes Data
The most compelling evidence comes from comparative effectiveness research:
Ceftazidime-avibactam vs. colistin 3:
- 30-day mortality: 9% vs. 32% (difference 23%, 95% CI 9%-35%, P=0.001)
- 64% probability of better outcome with ceftazidime-avibactam
- This 2018 CRACKLE study represents the highest-quality direct comparison available
Recent combination data 4:
- Colistin + ceftazidime-avibactam achieved 64.7% microbiological clearance
- Colistin + tigecycline achieved only 24.1% clearance (P=0.002)
- However, survival analysis showed colistin + meropenem had longer survival duration than colistin + ceftazidime-avibactam
Clinical Decision Algorithm
Step 1: Confirm CRE and Obtain Susceptibilities
- Identify carbapenemase type if possible (KPC, OXA-48, NDM, etc.)
- Obtain MIC for ceftazidime-avibactam
- Check for metallo-β-lactamase (MBL) production
Step 2: Severity Assessment
Severe infection (any of):
- Septic shock
- ICU admission required
- Bloodstream infection
- HAP/VAP
- High-risk host (immunosuppression, malignancy)
Non-severe infection:
- Complicated UTI without sepsis
- Intra-abdominal infection, stable
- Skin/soft tissue infection
Step 3: Treatment Selection
For KPC or OXA-48 producers (most common in US/Europe):
- First-line: Ceftazidime-avibactam monotherapy 1, 3
- Dose: Standard dosing per susceptibility
- Do NOT add combination therapy 1
For MBL producers (NDM, VIM, IMP):
- First-line: Ceftazidime-avibactam + aztreonam 1, 5
- Alternative: Cefiderocol (if susceptible)
- Aztreonam-avibactam shows 97.8% activity against MBL-DTR isolates 6
For non-severe infections:
- Consider older agents based on individual susceptibility (aminoglycosides for UTI, etc.) 1
- Reserve ceftazidime-avibactam for stewardship reasons
AVOID tigecycline-colistin combination for:
- Bloodstream infections (strong recommendation) 1
- HAP/VAP (strong recommendation) 1
- Any severe infection where better options exist
Step 4: When Ceftazidime-Avibactam is NOT Available or Resistant
Only in this scenario consider:
- Polymyxin-based combination (colistin + carbapenem if MIC ≤8 mg/L, or colistin + aminoglycoside)
- High-dose tigecycline (if pneumonia, use cautiously) 1
- Cefiderocol (if susceptible)
Critical Pitfalls to Avoid
Do not use tigecycline for BSI or HAP/VAP - This is explicitly contraindicated by guidelines and supported by FDA mortality data 1, 2
Do not add unnecessary combination therapy to ceftazidime-avibactam - Strong recommendation against this for susceptible isolates 1
Do not assume all CRE are the same - MBL producers require aztreonam addition; KPC/OXA-48 do not 1, 5
Do not use colistin as first-line when newer agents are available - Reserve for situations with no alternatives due to nephrotoxicity and inferior outcomes 7
Watch for resistance emergence - 24.1% ceftazidime-avibactam resistance reported in some centers 8; always confirm susceptibility
Nuances in the Evidence
While the 2025 study 4 showed better microbiological clearance with colistin + ceftazidime-avibactam versus colistin + tigecycline, it paradoxically found longer survival with colistin + meropenem. However, this conflicts with the stronger 2018 CRACKLE data 3 showing clear mortality benefit with ceftazidime-avibactam over colistin, and the guideline recommendations prioritize ceftazidime-avibactam monotherapy over any colistin-based regimen when the organism is susceptible 1.
The guideline's conditional recommendation reflects moderate/low quality evidence, but the direction is clear and consistent: newer β-lactam/β-lactamase inhibitors outperform older combinations for mortality and morbidity outcomes.